InterMune set to price secondary offering

|By:, SA News Editor

InterMune (ITMN) to offer 7.5M shares of common stock for public sale plus an optional 1.125M shares for underwriters.

The company will use the net proceeds to fund Esbriet (pirfenidone) commercialization activities including the product's eventual launch in the US, R&D projects and for general corporate purposes.